Prev Arrow Stocks

Cardinal Health Inc. ($CAH) Stock Forecast: Down 0.7% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is Cardinal Health Inc.?

Cardinal Health (CAH) is a healthcare services company that provides pharmaceutical and medical products to healthcare providers. The company operates in a sector heavily influenced by regulatory changes and market demand for healthcare services.

Why is Cardinal Health Inc. going down?

CAH stock is down 0.7% on Jul 15, 2024 14:46

  • The bearish movement in CAH stock today could be attributed to regulatory setbacks. Regulatory challenges can impact the company's operations and profitability, leading to negative investor sentiment.
  • Despite being highlighted as an undervalued dividend stock, the market might be reacting to specific concerns, overshadowing the potential long-term benefits of investing in dividend stocks.
  • The overall market improvement may have had a limited impact on CAH stock, indicating that company-specific factors are currently driving the stock price movement more significantly than broader market trends.
  • Investors should closely monitor any updates regarding regulatory issues and how Cardinal Health addresses them to gauge the future trajectory of the stock.

CAH Price Chart

CAH News

Reasons to Retain Cardinal Health ( CAH ) in Your Portfolio Now

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

https://www.zacks.com/stock/news/2301066/reasons-to-retain-cardinal-health-cah-in-your-portfolio-now

News Article Image Reasons to Retain Cardinal Health  ( CAH )  in Your Portfolio Now

The 7 Most Undervalued Dividend Stocks to Buy in July 2024

Dividend stocks have long been investor favorites. Not only do dividends provide a reliable stream of income but they also increase a portfolio’s returns over time. They get even more exciting if they’re undervalued dividend stocks. Since 1930, dividend stocks outperformed all other classes of stocks. The Hartford Funds found that over the last 95 years, stocks on the S&P 500 that initiated and raised their dividends have never had a losing decade. Through world wars and global pandemics, income-generating stocks were the best investments. No other stock can say the same. And it stands to reason. Dividend stocks to buy are successful businesses, and having gone through numerous business and economic cycles, have come through the trials intact. With capable management and a conservative outlook, they steered their companies well and shared their success — and profits — with shareholders. Below are three undervalued dividend stocks to buy in July. Despite the bull market and regardless of their performance, they now represent some of the best investments available.

https://investorplace.com/2024/07/the-7-most-undervalued-dividend-stocks-to-buy-in-july-2024/

News Article Image The 7 Most Undervalued Dividend Stocks to Buy in July 2024

Cardinal Health ( CAH ) Stock Declines While Market Improves: Some Information for Investors

Cardinal Health (CAH) concluded the recent trading session at $96.01, signifying a -0.9% move from its prior day's close.

https://www.zacks.com/stock/news/2298834/cardinal-health-cah-stock-declines-while-market-improves-some-information-for-investors

News Article Image Cardinal Health  ( CAH )  Stock Declines While Market Improves: Some Information for Investors

Cardinal Health Inc. Price History

15.06.2024 - CAH Stock was down 0.7%

  • The bearish movement in CAH stock today could be attributed to regulatory setbacks. Regulatory challenges can impact the company's operations and profitability, leading to negative investor sentiment.
  • Despite being highlighted as an undervalued dividend stock, the market might be reacting to specific concerns, overshadowing the potential long-term benefits of investing in dividend stocks.
  • The overall market improvement may have had a limited impact on CAH stock, indicating that company-specific factors are currently driving the stock price movement more significantly than broader market trends.
  • Investors should closely monitor any updates regarding regulatory issues and how Cardinal Health addresses them to gauge the future trajectory of the stock.

14.02.2024 - CAH Stock was down 5.1%

  • The increase in Cardinal Health's short interest by 13.87% may have contributed to the bearish movement as higher short interest can indicate a lack of confidence in the stock's performance.
  • The negative market sentiment towards Cardinal Health could be due to concerns about the company's ability to effectively manage its internal resource pool, as highlighted by another company's expansion of capabilities in healthcare system management.
  • Investors might be cautious about Cardinal Health's financial performance, given the company's recent report of 4.27% of all regular shares being sold short, indicating a potential lack of faith in its future growth prospects.
  • The overall market reaction to Cardinal Health's bearish movement could also be influenced by broader industry trends, such as the increasing focus on digital solutions in healthcare, as seen with collaborations in the pathology sector.

03.10.2023 - CAH Stock was up 8.6%

  • Cardinal Health reported Q1 FY24 adjusted EPS of $1.73, beating the consensus of $1.41.
  • The company raised its profit outlook for FY2024 after reporting increased profit in the pharmaceutical and medical segments.
  • Despite a slight decrease in Q1 profit compared to the same period last year, Cardinal Health beat Street estimates.
  • The non-GAAP EPS of $1.73 beat expectations, although revenue fell slightly short.
  • Overall, the bullish movement in CAH's stock can be attributed to the positive earnings report and the company's optimistic outlook for the future. The strong performance in the pharmaceutical and medical segments likely contributed to investor confidence in the stock.

17.07.2023 - CAH Stock was down 5.2%

  • The bearish movement in CAH stock today can be attributed to the following factors:
  • 1. Disappointing Q2 Revenue: Despite beating Wall Street's expectations for earnings, Cardinal Health reported lower-than-expected revenue in its fiscal fourth quarter. This could have led to a decrease in investor confidence and a subsequent decline in the stock price.
  • 2. Weight-Loss and Diabetes Drugs: While Cardinal Health attributed its strong Q4 growth to the increasing popularity of weight-loss and diabetes drugs in the GLP-1 class, it seems that this positive news was not enough to sustain the bullish momentum. Other factors may have overshadowed this positive development, leading to the bearish movement.
  • 3. Overall Market Sentiment: The broader market sentiment and trends in the healthcare sector could have also influenced the bearish movement in CAH stock. Factors such as regulatory changes, healthcare policy discussions, and market volatility can impact investor sentiment and contribute to market movements.
  • 4. External Factors: It's worth noting that the news articles provided do not directly mention any specific negative developments or events related to Cardinal Health. However, it's possible that external factors, such as market-wide concerns, global economic conditions, or industry-specific challenges, could have influenced the bearish movement in CAH stock.

30.05.2023 - CAH Stock was up 0.6%

  • The bullish movement in CAH's stock today can be attributed to the following factors:
  • 1. Institutional Investment: Allspring Global Investments Holdings LLC increased its stock position in Cardinal Health, indicating confidence in the company's future prospects. This positive sentiment from a major investor could have contributed to the bullish movement.
  • 2. Distribution Agreement: Cardinal Health signed a distribution agreement with Tivic Health Systems, leading to a surge in Tivic Health Systems' stock. This partnership could have generated optimism about Cardinal Health's growth potential and positively impacted its stock price.
  • 3. Market Performance: The overall healthcare services market has been performing well, with AmerisourceBergen receiving a composite rating upgrade. This suggests that the industry as a whole is outperforming other stocks, which could have influenced the bullish movement in CAH's stock.
  • 4. Market Sentiment: While not directly related to Cardinal Health, other stocks in the healthcare sector, such as Black Diamond Therapeutics and Centogene N.V., experienced significant gains. This positive sentiment in the sector could have spilled over to Cardinal Health, contributing to its bullish movement.

27.05.2023 - CAH Stock was down 1.8%

  • CAH had a strong bearish movement today.
  • Sotera Health announced the appointment of Jon Lyons as their new CFO, which is not directly related to CAH, but could have caused some investors to shift their focus to Sotera Health instead.
  • Despite hitting a 52-week high recently, CAH's bearish movement could be due to profit-taking by investors who are optimistic about the company's diversified product portfolio.

04.04.2023 - CAH Stock was down 4.8%

  • Today, CAH had a strong bearish movement. Here are some possible reasons why:
  • Despite beating Wall Street estimates for Q3 earnings and raising its annual profit forecast, the company's earnings and EPS were lower than the same period last year.
  • The market may have reacted negatively to the fact that the company's Q3 earnings were significantly lower than its Q1 earnings.
  • The market may have also reacted to the fact that the company's Q3 revenue growth was only 1.8% YoY, which was lower than expected.
  • It's possible that investors were disappointed that the company did not provide any updates on its plans to spin off its medical business.

04.04.2023 - CAH Stock was down 4.8%

  • Despite beating Wall Street estimates for the third quarter, CAH had a bearish movement, possibly due to the following reasons:
  • The company's earnings and EPS were lower compared to the same period last year, which could have disappointed investors.
  • Although the company raised its annual profit forecast, the market may have expected higher projections.
  • The positive news about the demand for specialty medicines in a post-pandemic market may not have been enough to offset the negative sentiment towards the company's financial performance.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.